These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8271402)

  • 1. [Targets and possible therapeutic interventions for HIV carriers].
    Kageyama S; Kurimura T
    Nihon Rinsho; 1993 Sep; 51 Suppl():351-6. PubMed ID: 8271402
    [No Abstract]   [Full Text] [Related]  

  • 2. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
    Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
    Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of expression of human immunodeficiency virus.
    Pavlakis GN; Felber BK
    New Biol; 1990 Jan; 2(1):20-31. PubMed ID: 2078551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tat and Rev: positive regulators of HIV gene expression.
    Rosen CA; Pavlakis GN
    AIDS; 1990 Jun; 4(6):499-509. PubMed ID: 2201316
    [No Abstract]   [Full Text] [Related]  

  • 5. The tat gene and protein of the human immunodeficiency virus type 1.
    Caputo A; Grossi MP; Rossi C; Campioni D; Balboni PG; Corallini A; Barbanti-Brodano G
    New Microbiol; 1995 Jan; 18(1):87-110. PubMed ID: 7760763
    [No Abstract]   [Full Text] [Related]  

  • 6. [Regulatory mechanism of HIV gene expression].
    Hatanaka M
    Nihon Rinsho; 1993 Sep; 51 Suppl():43-57. PubMed ID: 8271415
    [No Abstract]   [Full Text] [Related]  

  • 7. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.
    Li M; Li H; Rossi JJ
    Ann N Y Acad Sci; 2006 Oct; 1082():172-9. PubMed ID: 17145937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of HIV-based retrovirus vector].
    Hayashi T; Okamoto T
    Nihon Rinsho; 1993 Sep; 51 Suppl():615-20. PubMed ID: 8271447
    [No Abstract]   [Full Text] [Related]  

  • 9. The HIV-1 Tat transactivator protein: a therapeutic target?
    Fulcher AJ; Jans DA
    IUBMB Life; 2003 Dec; 55(12):669-80. PubMed ID: 14769003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector.
    Cara A; Rybak SM; Newton DL; Crowley R; Rottschafer SE; Reitz MS; Gusella GL
    Gene Ther; 1998 Jan; 5(1):65-75. PubMed ID: 9536266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy clinical trials for HIV.
    Statham S; Morgan RA
    Curr Opin Mol Ther; 1999 Aug; 1(4):430-6. PubMed ID: 11713756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing.
    Puttaraju M; Been MD
    Nucleic Acids Symp Ser; 1995; (33):49-51. PubMed ID: 8643395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy.
    Duan L; Zhu M; Ozaki I; Zhang H; Wei DL; Pomerantz RJ
    Gene Ther; 1997 Jun; 4(6):533-43. PubMed ID: 9231069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [RNA ligands for HIV proteins].
    Iwai S
    Tanpakushitsu Kakusan Koso; 1995 Jul; 40(10):1430-7. PubMed ID: 7568944
    [No Abstract]   [Full Text] [Related]  

  • 15. Structural RNA mimetics: N3'-->P5' phosphoramidate DNA analogs of HIV-1 RRE and TAR RNA form A-type helices that bind specifically to Rev and Tat-related peptides.
    Rigl CT; Lloyd DH; Tsou DS; Gryaznov SM; Wilson WD
    Biochemistry; 1997 Jan; 36(3):650-9. PubMed ID: 9012680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing.
    Puttaraju M; Been MD
    Nucleic Acids Symp Ser; 1995; (33):152-5. PubMed ID: 8643355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
    Peng H; Callison D; Li P; Burrell C
    Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of HIV-1 envelope protein synthesis by Tat and Rev in 293 cells.
    Natarajan V; Radjendirane V; Salzman NP
    Virology; 1993 Sep; 196(1):122-9. PubMed ID: 8356789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tat and rev differentially affect restricted replication of human immunodeficiency virus type 1 in various cells.
    Duan L; Oakes JW; Ferraro A; Bagasra O; Pomerantz RJ
    Virology; 1994 Mar; 199(2):474-8. PubMed ID: 8122376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.
    Southgate C; Zapp ML; Green MR
    Nature; 1990 Jun; 345(6276):640-2. PubMed ID: 2190099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.